Neuromyelitis Optica Spectrum Disorder Clinical Trial
— SAkuraSunOfficial title:
A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.
Status | Recruiting |
Enrollment | 8 |
Est. completion date | September 12, 2029 |
Est. primary completion date | March 31, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 11 Years |
Eligibility | Inclusion Criteria: - Age at screening 2-11 years, inclusive - Body weight at screening >=10 kg - For female patients of childbearing potential (postmenarchal): agreement to either remain completely abstinent (refrain from heterosexual intercourse) or to use a reliable means of contraception - Diagnosed as having NMOSD with AQP4 antibody seropositive status as defined by the Wingerchuk 2015 criteria Clinical evidence of at least one documented attack (including first attack) in the last year prior to screening - Neurological stability for >=30 days prior to both screening and baseline - Expanded Disability Status Scale (EDSS) 0 to 6.5 - For patients receiving a baseline immunosuppressant treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline Exclusion Criteria: - Pregnancy or lactation - Evidence of other demyelinating disease mimicking NMOSD - Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline - Evidence of chronic active hepatitis B or C - Evidence of untreated latent or active tuberculosis (TB) - Receipt of a live or live-attenuated vaccine within 6 weeks prior to baseline - History of severe allergic reaction to a biologic agent |
Country | Name | City | State |
---|---|---|---|
Argentina | Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan | Ciudad Autonoma Buenos Aires | |
Argentina | Clinica Universitaria Reina Fabiola | Cordoba | |
France | Centre Hospitalier Universitaire de Bicêtre | Le Kremlin-bicêtre | |
Italy | Fondazione Istituto Neurologico Mondino IRCCS | Pavia | Lombardia |
Italy | IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN | Roma | Lazio |
Poland | Uniwersyteckie Centrum Kliniczne | Gdansk | |
United Kingdom | Great Ormond Street Hospital for Children | London | |
United States | Children's Hospital Colorado. | Denver | Colorado |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Argentina, France, Italy, Poland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Summary of observed serum concentration [Cthrough] of satralizumab | Week 48 | ||
Primary | Apparent clearance [CL/F] of satralizumab | Week 48 | ||
Primary | Apparent volume of distribution [V/F] of satralizumab | Week 48 | ||
Primary | Area under the concentration-time curve [AUC] of satralizumab | Week 48 | ||
Secondary | Proportion of relapse-free patients by Week 48 | Week 48 | ||
Secondary | Annualized relapse rate (ARR), defined as the average number of relapses for each year of the study | Week 48 | ||
Secondary | Time to first relapse (TFR) after randomization, defined as the time from randomization until the first occurrence of relapse, as determined by the investigator | Week 48 | ||
Secondary | Time to relapse requiring rescue therapy | Week 48 | ||
Secondary | Change from baseline in Expanded Disability Status Scale (EDSS) at Weeks 24 and 48 | Baseline, Week 24, Week 48 | ||
Secondary | Change from baseline in visual acuity at Weeks 24 and 48 | Baseline, Week 24, Week 48 | ||
Secondary | Change from baseline in FACES Pain Rating Scale at Weeks 24 and 48 | Baseline, Week 24, Week 48 | ||
Secondary | Change from baseline in EuroQol 5-Dimension, Youth (EQ-5D-Y) score and its proxy at Weeks 24 and 48 | Baseline, Week 24, Week 48 | ||
Secondary | Incidence and severity of adverse events | Week 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT03002038 -
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04064944 -
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
|
Phase 2 | |
Recruiting |
NCT05414487 -
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
|
||
Not yet recruiting |
NCT05551598 -
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 2 | |
Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
Completed |
NCT01845584 -
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
|
Phase 2 | |
Completed |
NCT04660539 -
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 3 | |
Recruiting |
NCT05504694 -
Ofatumumab in AQP4-IgG Seropositive NMOSD
|
Phase 1/Phase 2 | |
Recruiting |
NCT05346354 -
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
|
Phase 2/Phase 3 | |
Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|
||
Completed |
NCT01500681 -
Maintenance Plasma Exchange for Neuromyelitis Optica
|
||
Not yet recruiting |
NCT06374264 -
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
|
N/A | |
Not yet recruiting |
NCT05891379 -
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
|
||
Recruiting |
NCT05909761 -
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
|
||
Completed |
NCT02276963 -
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
|
Phase 1 | |
Terminated |
NCT04155424 -
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
|
Phase 2/Phase 3 | |
Completed |
NCT02003144 -
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
|
Phase 3 | |
Completed |
NCT03819413 -
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital
|